Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 17, Issue 2, Pages 377-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2008.01.002
Keywords
-
Funding
- NCI NIH HHS [T32 CA009501, T32 CA009501-20] Funding Source: Medline
Ask authors/readers for more resources
Hepatocellular cancer (HCC) is the fifth-leading cause of cancer and the third-leading cause of cancer related deaths world-wide. Current treatment options are limited, as HCC has been shown to be a highly resistant type of cancer to most current treatment modalities. Novel approaches are being explored in the fields of gene therapy, viral oncolytics, radioembolization, and several new biologic therapies. This article summarizes these recent clinical findings and discusses what role they will have in the future treatment of HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available